On demand plerixafor is safe and effective for hematopoietic progenitor cell mobilization in patients with light chain amyloidosis at risk for mobilization failure with G-CSF alone

Bone Marrow Transplant. 2023 May;58(5):610-612. doi: 10.1038/s41409-023-01938-0. Epub 2023 Feb 24.

Authors

Affiliations

¹ Cleveland Clinic, Department of Hematology and Medical Oncology, Cleveland, OH, USA. [email protected].
² Cleveland Clinic, Department of Hematology and Medical Oncology, Cleveland, OH, USA.
³ University of Kansas, Department of Hematology and Medical Oncology, Kansas City, KS, USA.
⁴ Cleveland Clinic Florida, Department of Hematology and Medical Oncology, Maroone Cancer Center, Weston, FL, USA.

No abstract available

Publication types

Letter
Research Support, N.I.H., Extramural

MeSH terms

Amyloidosis* / therapy
Benzylamines / metabolism
Granulocyte Colony-Stimulating Factor / therapeutic use
Hematopoietic Stem Cell Mobilization
Hematopoietic Stem Cell Transplantation*
Hematopoietic Stem Cells / metabolism
Heterocyclic Compounds* / therapeutic use
Humans
Multiple Myeloma* / therapy

Substances

Granulocyte Colony-Stimulating Factor
Heterocyclic Compounds
Benzylamines

Grants and funding

TL1 DK132770/DK/NIDDK NIH HHS/United States